Business
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®
PORTLAND, Maine, April 02, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it is initiating Investigational Product use of Re-Tain®. The Company intends to use this opportunity to test market acceptance of the product through a controlled launch. This
About this update from Immucell Corporation
[{"type":"image","alt":"ImmuCell Corporation","displaySize":"","headline":null,"caption":"ImmuCell Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7ckduXNsI_qLHBNY2yY.og--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc","width":300,"height":36}},"lazy":false},{"type":"text","content":"PORTLAND, Maine, April 02, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it is initiating Investigational Product use of Re-Tain®.","length":391,"tagName":"p"},{"type":"text","content":"The Company intends to use this opportunity to test market acceptance of the product through a controlled launch. This initiative also helps the Company utilize available inventory before shelf-life expiration. This opportunity is not expected to generate significant revenue or profit.","length":286,"tagName":"p"},{"type":"text","content":"The Company made its Non-Administrative New Animal Drug Application (NADA) submission, that included its fourth submission of the CMC Technical Section, together with the minor technical sections covering All Other Information and Product Labeling during early January of 2025. Clearing inspectional observations at the facilities of the Company’s contract manufacturer is still the critical path constraint to NADA approval.","length":425,"tagName":"p"},{"type":"text","content":"“This investigational strategy allows us to collect product performance data on Re-Tain® while full NADA approval is pending the final stages of review,” commented Michael F. Brigham, President and CEO. “After all these years in drug development, we can soon begin to see how this product performs on farms.”","length":308,"tagName":"p"},{"type":"text","content":"Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):","length":77,"tagName":"p"},{"type":"text","content":"This Press Release contains “forward-looking statements” within the meanin...